New Research: Adverse Events and Compounded Meds
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
New Research: Adverse Events and Compounded Meds
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
In this episode, PSM Executive Director Shabbir Imber Safdar sits down with Dr. Kenneth McCall to explore his newly published study on the adverse events linked to compounded GLP-1 receptor agonists. Dr. McCall’s study, which analyzed data from the FDA Adverse Event Reporting System (FAERS) database, raises important safety questions about compounded semaglutide and tirzepatide. Tune in to learn about why compounded GLP-1s are so popular now, key findings from the FAERS data analysis, and future directions for safety and policy.
Pas encore de commentaire